107 related articles for article (PubMed ID: 7680279)
1. Alpha-fetoprotein half-life as a predictor of residual testicular tumor. Effect of the analytic strategy on test sensitivity and specificity.
See WA; Cohen MB; Hoxie LD
Cancer; 1993 Mar; 71(6):2048-54. PubMed ID: 7680279
[TBL] [Abstract][Full Text] [Related]
2. [Early changes in serum alpha-fetoprotein after chemotherapy in advanced testicular tumors].
Yamazaki H; Kondo N; Imanaka K; Kuroda A; Nakauchi K; Machida T
Nihon Hinyokika Gakkai Zasshi; 1990 Jul; 81(7):1010-6. PubMed ID: 1699019
[TBL] [Abstract][Full Text] [Related]
3. [Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer].
Neumann A; Keller T; Jocham D; Doehn C
Aktuelle Urol; 2011 Sep; 42(5):311-5. PubMed ID: 21809268
[TBL] [Abstract][Full Text] [Related]
4. Lectin-reactive alpha-fetoprotein (AFP-L3%) curability and prediction of clinical course after treatment of non-seminomatous germ cell tumors.
Kamoto T; Satomura S; Yoshiki T; Okada Y; Henmi F; Nishiyama H; Kobayashi T; Terai A; Habuchi T; Ogawa O
Jpn J Clin Oncol; 2002 Nov; 32(11):472-6. PubMed ID: 12499420
[TBL] [Abstract][Full Text] [Related]
5. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
de Wit R; Sylvester R; Tsitsa C; de Mulder PH; Sleyfer DT; ten Bokkel Huinink WW; Kaye SB; van Oosterom AT; Boven E; Vermeylen K; Stoter G
Br J Cancer; 1997; 75(3):432-5. PubMed ID: 9020492
[TBL] [Abstract][Full Text] [Related]
6. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
Beck SD; Foster RS; Bihrle R; Donohue JP
Urology; 2007 Mar; 69(3):557-9. PubMed ID: 17382165
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
You B; Fronton L; Boyle H; Droz JP; Girard P; Tranchand B; Ribba B; Tod M; Chabaud S; Coquelin H; Fléchon A
Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
[TBL] [Abstract][Full Text] [Related]
8. Importance of a new tumor marker TRA-1-60 in the follow-up of patients with clinical stage I nonseminomatous testicular germ cell tumors.
Gels ME; Marrink J; Visser P; Sleijfer DT; Droste JH; Hoekstra HJ; Andrews PW; Schraffordt Koops H
Ann Surg Oncol; 1997 Jun; 4(4):321-7. PubMed ID: 9181232
[TBL] [Abstract][Full Text] [Related]
9. [High alpha-fetoprotein persistence after orchiectomy. On a case of uncommon etiology].
Chierigo P; Puccetti O; Visonà A; Bassan F; Rahmati M; Lazzarotto M; Franzolin N
Urologia; 2010; 77 Suppl 17():27-31. PubMed ID: 21308671
[TBL] [Abstract][Full Text] [Related]
10. Significance of human chorionic gonadotropin, alpha-fetoprotein, and pregnancy-specific beta-1-glycoprotein in the detection of tumor relapse and partial remission in 126 patients with nonseminomatous testicular germ cell tumors.
de Bruijn HW; Sleijfer DT; Schraffordt Koops H; Suurmeijer AJ; Marrink J; Ockhuizen T
Cancer; 1985 Feb; 55(4):829-35. PubMed ID: 2578303
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of marker half-life in relapsed and nonrelapsed nonseminomatous germ cell testicular tumor patients undergoing chemotherapy.
Keskin S; Ekenel M; Başaran M; Bavbek S
Am J Clin Oncol; 2012 Aug; 35(4):369-72. PubMed ID: 22814307
[TBL] [Abstract][Full Text] [Related]
12. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy.
Murphy BA; Motzer RJ; Mazumdar M; Vlamis V; Nisselbaum J; Bajorin D; Bosl GJ
Cancer; 1994 May; 73(10):2520-6. PubMed ID: 7513603
[TBL] [Abstract][Full Text] [Related]
13. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?
Gerl A; Lamerz R; Clemm C; Mann K; Hartenstein R; Wilmanns W
Clin Cancer Res; 1996 Sep; 2(9):1565-70. PubMed ID: 9816334
[TBL] [Abstract][Full Text] [Related]
14. Serum lactate dehydrogenase isoenzyme 1 and prediction of death in patients with metastatic testicular germ cell tumors.
von Eyben FE; Blaabjerg O; Hyltoft-Petersen P; Madsen EL; Amato R; Liu F; Fritsche H
Clin Chem Lab Med; 2001 Jan; 39(1):38-44. PubMed ID: 11256799
[TBL] [Abstract][Full Text] [Related]
15. Actual half-life of alpha-fetoprotein as a prognostic tool in pediatric malignant tumors.
Han SJ; Yoo S; Choi SH; Hwang EH
Pediatr Surg Int; 1997; 12(8):599-602. PubMed ID: 9354734
[TBL] [Abstract][Full Text] [Related]
16. [Germ cell testicular tumors: understanding the kinetics of serum alpha-fetoprotein (AFP) during chemotherapy].
Riedinger JM; Eche N; Chevreau C; Fargeot P
Ann Biol Clin (Paris); 2008; 66(5):523-30. PubMed ID: 18957341
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma.
Stevens MJ; Norman AR; Dearnaley DP; Horwich A
J Clin Oncol; 1995 Jan; 13(1):87-92. PubMed ID: 7528272
[TBL] [Abstract][Full Text] [Related]
18. Serum α-fetoprotein in pediatric oncology: not a children's tale.
Ferraro S; Panzeri A; Braga F; Panteghini M
Clin Chem Lab Med; 2019 May; 57(6):783-797. PubMed ID: 30367785
[TBL] [Abstract][Full Text] [Related]
19. [Clinical presentation of testicular germinal cancer].
Fernández Gómez JM; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; Escaf Barmadah S; García Rodríguez J; Pérez García FJ; Rodríguez Faba O; Jalón Monzón A
Arch Esp Urol; 2002 Oct; 55(8):915-22. PubMed ID: 12455282
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic accuracy of preoperative alpha-fetoprotein as an ovarian tumor marker in children and adolescents: not as good as we thought?
Loh AH; Gee KW; Chua JH
Pediatr Surg Int; 2013 Jul; 29(7):709-13. PubMed ID: 23653236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
